<DOC>
	<DOC>NCT00004643</DOC>
	<brief_summary>OBJECTIVES: I. Evaluate the toxicity of cytarabine in patients with refractory systemic lupus erythematosus. II. Evaluate objective disease parameters, including serum complement levels, anti-DNA antibody titers, sedimentation rate, and the systemic lupus activity measure in these patients.</brief_summary>
	<brief_title>Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus</brief_title>
	<detailed_description>PROTOCOL OUTLINE: Subcutaneous cytarabine is given for 5 days. Patients are re-treated every 4 weeks for a maximum of 3 courses; those who relapse prior to the second course are re-treated every 3 weeks.</detailed_description>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Clinically documented active systemic lupus erythematosus demonstrating at least 4 revised diagnostic criteria Unresponsive to conventional therapy with nonsteroidal antiinflammatory drugs (NSAIDs), topical corticosteroids, and antimalarials Intolerable side effects from corticosteroids or other immunosuppressive drugs Failure on immunosuppressives not required No lifethreatening disease, e.g.: Lupus cerebritis Rapidly progressive glomerulonephritis Prior/Concurrent Therapy No concurrent other DNA synthesis inhibitors, NSAIDs, and prednisone continued on study Patient Characteristics Hematopoietic: WBC at least 2000; Platelets at least 100,000 Renal: Creatinine clearance at least 20 mL/min Other: No major infection within 2 weeks prior to entry Negative pregnancy test required of fertile women Effective contraception required of fertile women. Advised for men during and for 75 days after therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 1999</verification_date>
	<keyword>arthritis &amp; connective tissue diseases</keyword>
	<keyword>immunologic disorders and infectious disorders</keyword>
	<keyword>rare disease</keyword>
	<keyword>systemic lupus erythematosus</keyword>
</DOC>